Panbela Therapeutics Inc
NASDAQ:PBLA
Intrinsic Value
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PBLA.
Panbela Therapeutics Inc's market capitalization is 1.5m USD.
PBLA stock price is 0.44 USD.
PBLA.
PBLA. Open DCF Valuation
PBLA. Open Relative Valuation
PBLA.
PBLA has negative Free Cash Flow for the last twelve months.
PBLA's long-term liabilties (13m USD) exceed its long-term assets (11m USD).
PBLA has negative Operating Income for the last twelve months.
PBLA has negative Net Income for the last twelve months.
PBLA's ROE (Return on Equity) has significantly increased in the last 3 years from -126% to 437%.
PBLA's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -2 226% to -2 862%, and is approaching profitability.
PBLA's ROE (Return on Equity) for the past 12 months is very high and is equal to 437%.
PBLA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 862%.
PBLA has positive Net Debt. This means that the company has more debt (4m USD) than cash and short-term investments (910k USD).
PBLA's short-term liabilties (9m USD) exceed its short-term assets (2m USD).
PBLA has very high three-year average ROE (Return on Equity): 6 833%. The company is very efficient at transforming stockholders' equity into net income.
PBLA has negative three-year average ROIC (Return on Invested Capital): -2 354%. The company is not efficient at using invested capital to generate operating income.
PBLA's D/E (Debt to Equity) is very low and is equal to -1.69.
PBLA's Altman Z-Score is very low and is equal to -18.58.
Fundamental Analysis
Panbela Therapeutics Inc
Balance Sheet Decomposition
Panbela Therapeutics Inc
| Current Assets | 1.9m |
| Cash & Short-Term Investments | 910k |
| Receivables | 160k |
| Other Current Assets | 820k |
| Non-Current Assets | 8.7m |
| Other Non-Current Assets | 8.7m |
| Current Liabilities | 8.9m |
| Accounts Payable | 6.6m |
| Accrued Liabilities | 1.3m |
| Other Current Liabilities | 1m |
| Non-Current Liabilities | 4.2m |
| Long-Term Debt | 4.2m |
Earnings Waterfall
Panbela Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-23.8m
USD
|
|
Operating Income
|
-23.8m
USD
|
|
Other Expenses
|
260k
USD
|
|
Net Income
|
-23.5m
USD
|
Free Cash Flow Analysis
Panbela Therapeutics Inc
PBLA Profitability Score
Profitability Due Diligence
Panbela Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Panbela Therapeutics Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
PBLA Solvency Score
Solvency Due Diligence
Panbela Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Panbela Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PBLA Price Targets Summary
Panbela Therapeutics Inc
Ownership
PBLA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PBLA Price
Panbela Therapeutics Inc
| Average Annual Return | -19.27% |
| Standard Deviation of Annual Returns | 77.69% |
| Max Drawdown | -100% |
| Market Capitalization | 1.5m USD |
| Shares Outstanding | 3 481 300 |
| Percentage of Shares Shorted | 3.07% |
Company Profile
Panbela Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.
You don't have any saved screeners yet
